Grady Mike, Katz Laurence Barry, Cameron Hilary, Levy Brian Leonard
LifeScan Scotland Ltd, Inverness, United Kingdom.
LifeScan Inc, West Chester, PA, United States.
JMIR Diabetes. 2017 Aug 7;2(2):e19. doi: 10.2196/diabetes.7454.
Mobile diabetes apps enable health care professionals (HCPs) to monitor patient progress, offer remote consultations, and allow more effective and informed treatment decisions between patients and HCPs. The OneTouch Reveal app aggregates data from a blood glucose meter and provides analytics to help patients and HCPs visualize glycemic trends and patterns, enabling more informed treatment and lifestyle decisions. The app also allows patients and HCPs to keep connected by exchanging text messages (short message service [SMS]) or progress reports via email.
The primary objective of our study was to assess changes in glycemic control and overall experiences of patients and HCPs using the app in conjunction with the wireless OneTouch Verio Flex blood glucose meter.
We randomly assigned 137 adults with type 1 (T1DM) or type 2 diabetes mellitus (T2DM) and a glycated hemoglobin (HbA) level of ≥7.5% and ≤11.0% to use the glucose meter alone or glucose meter plus the app for 24 weeks. The meter + app group were scheduled to receive diabetes-related text messages from their HCP every 2 weeks (total of 12 texts). Clinical measures and self-reported outcomes were assessed during face-to-face clinic visits between the participant and a diabetes nurse at baseline, week 12, and week 24.
In 128 completed participants, HbA decreased after 12 and 24 weeks in both the meter-only (n=66) (0.56% and 0.55%, respectively) and meter + app groups (n=62) (0.78% and 0.67%, respectively) compared with baseline (each P<.001). The difference in HbA reduction between the 2 groups was not statistically significant at 12 or 24 weeks (P=.12 and P=.45, respectively). However, the decrease in HbA was greater in T2DM participants using the meter + app after 12 weeks (1.04%) than in T2DM participants using the meter alone (0.58%; P=.09). In addition, decrease in HbA in participants using the meter + app who received at least 10 diabetes-related text messages (1.05%) was significantly greater than in meter-only participants (P<.01).
Use of the OneTouch Verio Flex glucose meter alone or in combination with the OneTouch Reveal diabetes app was associated with significant improvements in glycemic control after 12 and 24 weeks. Improvements using the app were greatest in participants with T2DM and those participants who received the highest number of HCP text messages. This study suggests that real-time availability of patient data and the ability to send personalized diabetes-related text messages can assist HCPs to improve glycemic control in patients between scheduled visits.
Clinicaltrials.gov NCT02429024; https://clinicaltrials.gov/ct2/show/NCT02429024 (Archived by WebCite at http://www.webcitation.org/6sCTDRa1l).
移动糖尿病应用程序使医疗保健专业人员（HCPs）能够监测患者进展、提供远程咨询，并使患者与HCPs之间做出更有效且明智的治疗决策。OneTouch Reveal应用程序汇总来自血糖仪的数据，并提供分析以帮助患者和HCPs直观了解血糖趋势和模式，从而做出更明智的治疗和生活方式决策。该应用程序还允许患者和HCPs通过交换短信（短消息服务 [SMS]）或通过电子邮件发送进展报告来保持联系。
我们研究的主要目的是评估使用该应用程序结合无线OneTouch Verio Flex血糖仪时患者和HCPs的血糖控制变化及总体体验。
我们将137名糖化血红蛋白（HbA）水平≥7.5%且≤11.0%的1型糖尿病（T1DM）或2型糖尿病（T2DM）成年患者随机分为单独使用血糖仪组或血糖仪加应用程序组，为期24周。血糖仪 + 应用程序组计划每2周从其HCP接收糖尿病相关短信（共12条）。在基线、第12周和第24周参与者与糖尿病护士进行面对面门诊就诊期间评估临床指标和自我报告结果。
在128名完成研究的参与者中，与基线相比，仅使用血糖仪组（n = 66）（分别为0.56%和0.55%）和血糖仪 + 应用程序组（n = 62）（分别为0.78%和0.67%）在第12周和第24周时HbA均下降（各P <.001）。两组之间HbA降低的差异在第12周或第24周时无统计学意义（分别为P =.12和P =.45）。然而，使用血糖仪 + 应用程序的2型糖尿病参与者在第12周后HbA的降低幅度（1.04%）大于仅使用血糖仪的2型糖尿病参与者（0.58%；P =.09）。此外，接收至少10条糖尿病相关短信的使用血糖仪 + 应用程序的参与者HbA的降低幅度（1.05%）显著大于仅使用血糖仪的参与者（P <.01）。
单独使用OneTouch Verio Flex血糖仪或与OneTouch Reveal糖尿病应用程序联合使用在第12周和第24周后均与血糖控制的显著改善相关。使用该应用程序时，2型糖尿病参与者以及接收HCP短信数量最多的参与者改善最为明显。本研究表明患者数据的实时可用性以及发送个性化糖尿病相关短信的能力可帮助HCPs在预定就诊之间改善患者的血糖控制。
Clinicaltrials.gov NCT02429024；https://clinicaltrials.gov/ct2/show/NCT02429024（由WebCite存档于http://www.webcitation.org/6sCTDRa1l）
Zotero 插件
